FIELD: biotechnology.
SUBSTANCE: the invention relates to an anti-CD22 antibody-maitansine conjugate and pharmaceutical compositions comprising such a conjugate for carcinoma, sarcoma, leukemia or lymphoma treatment.
EFFECT: a new combination for carcinoma, sarcoma, leukemia or lymphoma treatment.
26 cl, 26 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ALDEHYDE MARKED IMMUNOGLOBULIN POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2606016C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATION | 2007 |
|
RU2436796C9 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| COMPOSITIONS AND METHODS RELATING TO DRUG CONJUGATES WITH ANTI-CD19 ANTIBODIES | 2019 |
|
RU2806333C2 |
| PEPTIDOMIMETIC COMPOUNDS AND THEIR CONJUGATES OF ANTIBODIES WITH DRUGS | 2014 |
|
RU2689388C1 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| CONJUGATES OF BINDER (ADC) WITH KSP INHIBITORS | 2014 |
|
RU2698697C2 |
| LIGAND-CYTOTOXIC DRUG CONJUGATE, PRODUCTION METHOD AND USE THEREOF | 2015 |
|
RU2685728C2 |
| STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | 2015 |
|
RU2680238C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
